Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Seminars in Thoracic and Cardiovascular Surgery
- Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.J Clin Oncol. 2008; 26: 3552-3559
- Disparities in Guideline-Concordant Treatment for Pathologic N1 Non-Small Cell Lung Cancer.Ann Thorac Surg. 2020; 109: 1512-1520
Toubat O.D.L., Ding K., et al. Benefit of Adjuvant Chemotherapy for Resected Pathologic N1 Non-Small Cell Cancer Is Unrecognized: A Subgroup Analysis of the JBR10 Trial. Semin Thorac Cardiovasc Surg. In press.
- Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer.N Engl J Med. 2005; 352: 2589-2597
- Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer.N Engl J Med. 2020; 383: 1711-1723
- Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.Lancet. 2021; 398: 1344-1357
Publication stageIn Press Journal Pre-Proof
Classification: Invited commentary
Funding Statement: No funding was received for this work.
Conflicts of Interest: None